Clay Siegall Advances Research On Cancer Treatment

Clay Siegall Advances Research On Cancer Treatment

In 1998, Dr. Clay Siegall’s dream of establishing an institution that would be at the forefront in the efforts to find a solution for cancer came true after he was successfully able to establish Seattle Genetics. Dr. Clay Siegall acts as the Chairman of the board of Directors, President, and the Chief Executive Officer of the company. He founded Seattle Genetics after realizing that there existed various challenges in the medical industry which had not been addressed accordingly, and therefore, more people in the society were suffering without the realization of the doctors.

Dr. Clay Siegall is a leader, and it is this quality that continues to motivate him each day. For instance, under his management, the company has ended up successfully establishing a network of therapies that target the changes that occur within the antibodies leading to cancer. One of the most important treatments for cancer that is currently being used on the patients is ADCETRIS. The particular therapy was hastily approved by the FDA in 2011 after the government saw the great efforts that had been undertaken by Dr. Clay Siegall to make the world a much better place for those who were affected by cancer.

The decision to embrace the ADC technology in the process of coming up with a cure has led Seattle genetics to rise above other firms that were initially involved in the development of cancer medication. The pain that Dr. Clay Siegall saw his father undergo when he was sick is what made him have such a great push for desiring to ensure that others who had the same complication do not end up suffering like his father. Success in business requires a lot of capital.

Dr. Clay Siegall has led his organization to raise approximately $675 million by requesting for funds from both the public and private companies and also the public offerings of the firm in 2001. Dr. Clay Siegall initially worked from 1991 to 1997 at the Bristol Myers Pharmaceuticals Research Institute, and then he joined the National Institute of Health where worked for about three years. At Alder Bio Pharmaceuticals, Dr. Clay Siegall is the chairman of the board of directors. In addition to his success record, he has managed publish 70 publications.